Results 141 to 150 of about 68,398 (251)

Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using ²¹³Bi-Anti-CD20 Monoclonal Antibody. [PDF]

J Nucl Med, 2023
Havlena GT, Kapadia NS, Huang P, Song H, Engles J, Brechbiel M, Sgouros G, Wahl RL.   +7 more
europepmc   +1 more source

A Case Report of a Patient With Recalcitrant Pemphigus Vulgaris Treated With Rituximab

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pemphigus vulgaris may demonstrate differential treatment responses across disease sites. In this case, cutaneous lesions responded to high‐dose corticosteroids, whereas refractory oral disease required rituximab to achieve remission, highlighting the need for individualized, multimodal therapy to achieve sustained disease control.
Mahlatse Cordelia Kgokolo, Lesedi Makgwethele Nevondo, Michaela Beetge, Razia A. G. Khammissa   +3 more
wiley   +1 more source

The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia

Brazilian Journal of Infectious Diseases
Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of ...
Thiago Carlos Gonçalves Rego, Celso Mitsushi Massumoto, Rodrigo Siqueira Batista, Larissa Hanauer de Moura, Lygia Maria Costa Soares, Andréia Patrícia Gomes   +5 more
doaj   +1 more source

Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti-SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms. [PDF]

Infect Drug Resist, 2023
Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J.   +17 more
europepmc   +1 more source

Anti-CD20 Monoclonal Antibody [PDF]

, 2020
openaire   +1 more source

Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi, Stephen Twumasi, Linda K. Olaga, Benedict Sackey, Daniel N. M. Antonio, Richard O. Ansah, Eugene A. Ansah, John A. Sah, Enoch O. Anto, Yvonne Anang‐Quartey, Antoinette Koomson, Angela Opoku, Godfred A. Donkor, Paulina Duah, Ama G. Boadu, Samuel Essien‐Baidoo, Wina I. O. Boadu, Lilian A. Boateng   +17 more
wiley   +1 more source

CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

OncoImmunology
Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are being intensively investigated.
Malgorzata Bobrowicz, Aleksandra Kusowska, Marta Krawczyk, Andriy Zhylko, Christopher Forcados, Aleksander Slusarczyk, Joanna Barankiewicz, Joanna Domagala, Matylda Kubacz, Michal Šmída, Lenka Dostalova, Katsiaryna Marhelava, Klaudyna Fidyt, Monika Pepek, Iwona Baranowska, Anna Szumera-Cieckiewicz, Else Marit Inderberg, Sébastien Wälchli, Monika Granica, Agnieszka Graczyk-Jarzynka, Martyna Majchrzak, Marcin Poreba, Carina Lynn Gehlert, Matthias Peipp, Malgorzata Firczuk, Monika Prochorec-Sobieszek, Magdalena Winiarska   +26 more
doaj   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Patients with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are burdened by immunodeficiency due to treatment and underlying disease. Infection‐related mortality remains a significant concern for patients' overall survival (OS). Methods This Swedish, population‐based study examined incidence of infections and OS in
Ingrid Glimelius, Love Tätting, Jonatan Freilich, M. Natalia Stelmaszuk, Qian Yang, Anna Deleskog, Sigurður Y. Kristinsson   +6 more
wiley   +1 more source

CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality

Journal of Hematology & Oncology
Despite the paradigm-shifting success of anti-CD20 monoclonal antibodies like rituximab, limitations such as antigen loss, impaired host immune effector functions, and resistance remain key challenges in non-Hodgkin lymphoma (NHL).
Leila Omidvar, Ali Hussein Mer, Yousef Mirzaei, Mohammad-Reza Sanaye-Pasand, Saeed Jahandideh, Mahmoud Hassani, Meghdad Abdollahpour-Alitappeh   +6 more
doaj   +1 more source